Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,990.00    -10.00 (-0.20%)
Bid:
4,950.00
Ask:
5,030.00
Spread: 80.00 (1.616%)
Market Cap: £332.37m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Acquisition

22 Jan 2015 07:00

RNS Number : 8414C
Judges Scientific PLC
22 January 2015
 

Judges Scientific plc

 

ACQUISITION OF ARMFIELD LIMITED

 

22 January 2015

 

 

 

JUDGES SCIENTIFIC plc

("Judges Scientific", "Judges" or the "Group")

 

ACQUISITION OF ARMFIELD LIMITED

 

 

Judges Scientific, the parent company of a group engaged in the design, manufacture and sale of scientific instruments, announces that it has today acquired 100% of the issued share capital of Armfield Limited ("Armfield"), a Hampshire-based instrument maker. Armfield designs and markets engineering equipment and research instruments for educational applications, together with research and development systems focused on the food, beverage, dairy, vegetable oils and pharmaceutical industries.

 

The acquisition, which is expected to be earnings enhancing with immediate effect, was completed for a cash consideration of £8.28 million and an earn-out capped at £1.51 million (the "Acquisition"). An additional payment will be made to reflect any excess working capital over and above the ongoing requirements of the business; Judges expects such payment to be covered by the cash inherited at the completion date. A further payment capped at £360,000 may become due if the triennial actuarial valuation of Armfield's defined benefit pension fund as at 31 March 2017 shows a reduction in the yearly contribution required to eliminate its funding deficit. The defined benefit scheme closed to new members with effect from 2001 and closed to new accrual in 2006.

 

Information on Armfield

 

Armfield specialises in the design, production and sale of engineering equipment and teaching instruments used by universities and technical colleges for educational and research projects. Products encompass an extensive range of disciplines including food technology, chemical, mechanical, environmental and civil engineering. Armfield also designs and manufactures R&D systems used in various industries including the food and drink and pharmaceutical sectors. The educational segment of the business accounts for approximately three quarters of total sales.

 

All products are designed by Armfield, manufactured in the UK and sold worldwide directly, through agents or through Armfield's US subsidiary, Armfield Inc., based in Clarksburg, New Jersey.

 

Armfield was established in Ringwood, Hampshire, in 1875 and started making educational instruments in 1963. The company has been the subject of two management buy-outs, initially in 1981 and subsequently in 1994 when it was purchased by Chris Addis, currently Managing Director, and Simon Farrow, currently Finance Director. Both Mr Addis and Mr Farrow have agreed to continue in their respective roles following completion.

 

Armfield's audited accounts for the financial year to 31 December 2013 show revenues of £12.2 million and pre-tax profits of £1.3 million. Operating profit for the same period, adjusted to eliminate non-recurring items and to reflect Armfield's ongoing cost base within the Judges group, would have totalled £1.66 million. The accounts show net tangible assets of £3 million, including cash of £2.56 million. The earn-out will amount to £1.51 million if Armfield has generated adjusted operating profits of £1.96 million or more in respect of the twelve month period to 31 December 2014, reducing by five times any shortfall below £1.96 million. Half of the earn-out will be paid in cash and half through the issue of new Ordinary shares ("Ordinary Shares") in Judges at a price of 2055p per Ordinary Share, based on the prevailing price of Judges' Ordinary Shares on the day the headline terms of the Acquisition were agreed. For accounting purposes, fluctuations in the share price will have a commensurate impact on the book value of the earn-out cap.

 

Financing of the Acquisition

 

The Acquisition and associated transaction costs are being financed from existing cash resources and an additional £4 million drawn down from the £10 million acquisition facility recently agreed with Lloyds Bank Corporate Markets. As explained in the announcement of 23 December 2014 in respect of that facility, the new debt structure avoids the need to maintain large unproductive cash balances and this transaction will result in a reduction of cash in hand.

 

The Board believes that Armfield is an excellent business with a strong global brand, a powerful international distribution network and an excellent reputation for quality and service.

 

Alex Hambro, Chairman of Judges, commented:

 

"Armfield is a world class company, with an acknowledged reputation for excellence in the educational sector, and its impact on the Group's financial performance should be significant. We are delighted to welcome Chris Addis and Simon Farrow to Judges' expanding management team."

 

For further information please contact:

Judges Scientific Plc

David Cicurel, CEO

Tel: 01342 323 600

 

Shore Capital (Nominated Adviser & Broker)

Pascal Keane

Edward Mansfield

Tel: 020 7408 4090

 

Cardew Group (Financial Public Relations)

Georgina Hall

Tel: 020 7930 0777 or 07740 720 462

 

Websites:

Judges Scientific: www.judges.uk.com 

Armfield: www.armfieldonline.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUUONRVVAAURR
Date   Source Headline
7th Jun 20133:24 pmRNSDirector/PDMR Shareholding
29th May 20135:17 pmRNSResult of AGM
10th May 20134:06 pmRNSDirector/PDMR Shareholding
12th Apr 20133:30 pmRNSIssue of Equity
9th Apr 201311:59 amRNSDirector/PDMR Shareholding
22nd Mar 20137:00 amRNSFinal Results
8th Mar 201311:30 amRNSNotice of Results
7th Mar 20132:41 pmRNSDirector/PDMR Shareholding
8th Feb 20133:54 pmRNSDirector/PDMR Shareholding
24th Jan 20137:00 amRNSTrading Statement
17th Jan 201310:55 amRNSIssue of Equity
14th Jan 20132:43 pmRNSIssue of Equity
8th Jan 20133:24 pmRNSDirector/PDMR Shareholding
17th Dec 20122:11 pmRNSIssue of Equity
10th Dec 20123:28 pmRNSDirector/PDMR Shareholding and issue of equity
4th Dec 20123:06 pmRNSIssue of Equity
21st Nov 20127:00 amRNSTrading Statement
8th Nov 20125:22 pmRNSDirector/PDMR Shareholding
5th Nov 20122:24 pmRNSDirector/PDMR Shareholding
5th Nov 201210:14 amRNSDirector's Details
29th Oct 20122:22 pmRNSDirector/PDMR Shareholding
9th Oct 201212:05 pmRNSDirector/PDMR Shareholding
3rd Oct 20122:28 pmRNSHolding(s) in Company
25th Sep 20126:28 pmRNSHolding(s) in Company
25th Sep 20127:00 amRNSHalf Yearly Report
7th Sep 20123:19 pmRNSDirector/PDMR Shareholding
6th Sep 201211:31 amRNSNotice of Results
31st Aug 20129:52 amRNSHolding(s) in Company
24th Aug 20127:00 amRNSDirector/PDMR Shareholding
22nd Aug 20123:44 pmRNSHolding(s) in Company
21st Aug 20127:00 amRNSDirector/PDMR Shareholding
8th Aug 20123:13 pmRNSDirector/PDMR Shareholding
23rd Jul 20125:34 pmRNSDirector/PDMR Shareholding
18th Jul 20127:00 amRNSTrading Statement
9th Jul 20125:43 pmRNSDirector/PDMR Shareholding
29th Jun 201212:17 pmRNSDirector/PDMR Shareholding
29th Jun 20127:00 amRNSDirector/PDMR Shareholding
22nd Jun 20127:00 amRNSDirector/PDMR Shareholding
21st Jun 20125:17 pmRNSHolding(s) in Company
7th Jun 20124:36 pmRNSDirector/PDMR Shareholding
30th May 20125:16 pmRNSResult of AGM
22nd May 20126:18 pmRNSDirector/PDMR Shareholding
17th May 20123:31 pmRNSHolding(s) in Company
17th May 20123:16 pmRNSHolding(s) in Company
16th May 20125:14 pmRNSHolding(s) in Company
11th May 201212:07 pmRNSDirector/PDMR Shareholding
10th May 201210:00 amRNSIssue of Equity
9th May 201211:33 amRNSHolding(s) in Company
23rd Apr 20125:24 pmRNSExercise of Options
18th Apr 20125:46 pmRNSExercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.